Theralase Technologies (TSXV:TLT) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:TLT Theralase Technologies Inc TSXV:TLT
45 GF Score
Price C$0.26
GF Value C$0.18
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Theralase Technologies Quality Rank Related Terms

TSXV:TLT
45GF Score
Theralase Technologies Inc TSXV:TLT
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Theralase Technologies (TSXV:TLT) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of C$0.26 is trading 41.7% above its estimated GF Value™ of C$0.18. GuruFocus considers Theralase Technologies to be Significantly Overvalued.

Key valuation signals for TSXV:TLT:

  • Quality Rank:
  • GF Value™: C$0.18 vs. price of C$0.26 (41.7% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the TSXV:TLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TLTFF:USATTX:Germany
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
45GF Score

Get the complete analysis for TSXV:TLT

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.26
Price
C$0.18
GF Value